Sponsor:
Eclipse Life Sciences, Inc.
Code:
NCT06536491
Conditions
Diabetic Macular Edema
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
EC-104 high dose
EC-104 low dose
Dexamethasone intravitreal implant
Brief summary:
Conditions
Diabetic Macular Edema
Study ID
NCT06536491
Start date
Aug 19, 2024
Status verified date
Jan, 2025
Completion date
Dec 31, 2025
Anticipated
Primary completion date
Dec 31, 2025
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
75 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: EC-104 high dose
experimental: EC-104 low dose
active comparator: Dexamethasone intravitreal implant
Interventions
EC-104 high dose
EC-104 low dose
Dexamethasone intravitreal implant
Primary outcome measure
Central contacts
Locations
Retina Associates of Florida, LLC
Recruiting
Tampa, Florida, United States, 33609
Sponsor
Eclipse Life Sciences, Inc.
Last update posted
Jan 22, 2025
Last verified
Jan, 2025
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Eclipse Life Sciences, Inc. on 2025-01-22.